News for Sage Therapeutics, Inc. (SAGE)

Significant Transaction by FMR LLC (Trades, Portfolio) On February 28, 2025, FMR LLC (Trades, Portfolio) executed a notable reduction in its holdings of Sage Th

On February 28, 2025, Morgan Stanley made a significant move by reducing its stake in Sage Therapeutics Inc (SAGE). The firm decreased its holdings by 3,582,018

On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) executed a significant transaction involving Sage Therapeutics Inc. The firm reduced its holdings

Transaction Overview On December 31, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving Sage Therapeutics Inc (SAGE), a clinical-sta

SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

Revenue: $11.4 million in Q4 2024, a 4% increase from Q3 2024; $36.1 million for the full year 2024.R&D Expenses: $37 million in Q4 2024.SG&A Expenses: $54 mil

Start Time: 16:30 January 1, 0000 5:19 PM ETSage Therapeutics, Inc.

The following slide deck was published by Sage Therapeutics, Inc.

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On December 31, 2024, Vanguard Group Inc executed a significant transaction involving Sage Therapeutics Inc (SAGE), reducing its holdings by 922,280 shares. The

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Sage Therapeutics, Inc. (Nasdaq: SAGE) (”œSage” or ”œthe Company”), today announced that its Board of Directors has initiated a process to explore strate

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sag

Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.

**media[521482]**

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. Read more here.

Analysis of Sage Therapeutics' financials and pipeline setbacks, including an unsolicited offer from Biogen, suggest a hold for investors. Click here to read.